Clinical trials: FOLFOX
Colorectal Cancer
Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime
Oxaliplatin is a cytotoxic platinum compound and is one of the chemotherapeutic agent used in advanced colorectal cancer. It is used combined with Fluorouracil (5 FU) and Leucovorin.
- Trial name
- PENCOLA (NCT03542136)
- Testing
- VibrosSense Meter®
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Lund University Hospital
BRCA Gene Rearrangement
BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss.
- Trial name
- NCT03838406
- Testing
- BRCA 1, Chemotherapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chung-Ang University
Metastatic Breast Cancer
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
- Trial name
- NCT01937507
- Testing
- HAI with FOLFOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Western Regional Medical Center
Pancreas Cancer
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.
- Trial name
- NCT03760614
- Testing
- Entinostat, FOLFOX regimen
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Colorectal Cancer
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.
- Trial name
- OPTIPRIME (NCT03584711)
- Testing
- FOLFOX + panitumumab
- Where
- 124 sites in France, Martinique
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer Metastatic
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
To determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and the toxicity profile (NCI CTCAE v5.0 and immune related adverse events) of i.t.
- Trial name
- ISILI (NCT03982121)
- Testing
- FOLFOX regimen, Nivolumab, Ipilimumab
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Liver Metastases, Colorectal Cancer
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
- Trial name
- MT201-204 (NCT00866944)
- Testing
- Adecatumumab, Adecatumumab and FOLFOX, FOLFOX 4
- Where
- 16 sites in France, Germany
- Volunteers
- 35 people
- Sponsor
- Amgen Research (Munich) GmbH
Colon Cancer
The Inland Northwest Colon Cancer Survivor's Study
The overall purpose of this study was to address the following questions by describing the trajectory of early survivorship in individuals who undergo both surgical and medical management of colon cancer.
- Trial name
- NCT01775254
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Washington State University
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib
Stratification for F-L Therapy After LT
Objective: To stratify recipients who underwent adjuvant FOLFOX plus lenvatinib (F-L) therapy following liver transplantation (LT) for hepatocellular carcinoma and provide guidance for clinical adjuvant therapy.
- Conditions
- Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib, Machine Learning
- Trial name
- NCT06564103
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Colorectal Cancer, Gastric Cancer
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for…
- Conditions
- Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer
- Trial name
- NCT04526886
- Testing
- Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastroesophageal Cancer, Gastric Cancer
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric…
- Trial name
- NCT00673673
- Testing
- FOLFOX, bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Neoplasms Pancreatic
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG.
- Trial name
- NCT04151277
- Testing
- FOLFOX-A, Gemcitabe and Abraxane, G-CSF
- Where
- 30 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Judith Dixon-Hughes
Colorectal Cancer
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.
- Trial name
- CORE 2 (NCT00479752)
- Testing
- FOLFOX4 (Oxaliplatin), Cetuximab
- Where
- 24 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 151 people
- Sponsor
- Central European Cooperative Oncology Group
Metastatic Colorectal Cancer
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks…
- Trial name
- EGIA-003 (NCT06225843)
- Testing
- Sotevtamab, FOLFOX
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Alethia Biotherapeutics
Colorectal Cancer
A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease…
- Trial name
- NCT00192075
- Testing
- Gemcitabine, avastin, 5FU/folinic acid
- Where
- 15 sites in United States
- Volunteers
- 84 people
- Sponsor
- Eli Lilly and Company
Advanced Colorectal Carcinoma
Phase I FOLFOX Combination
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal…
- Trial name
- NCT00499850
- Testing
- ZD6474 (vandetanib), 5-Fluorouracil, Leucovorin
- Where
- 4 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Genzyme, a Sanofi Company
Colorectal Cancer
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without…
- Trial name
- C-CLASSIC (NCT04262635)
- Testing
- Cetuximab, Capecitabine, Cetuximab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University